Adare Pharma divests Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x

Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.

ENPICOM secures extended financing from current investors

Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions

Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData

Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

Biotium introduces novel antibody labeling Kits for efficient labeling of IgM antibodies

Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes

Moderna files for FDA authorization of its Covid-19 Vaccine

Supply readiness follows months of manufacturing to ensure timely and ample supply

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya